AI Article Synopsis
- Endometrial papillary serous carcinoma (EPSC) is a rare type of gynecological cancer that often spreads to the lungs, liver, and bones, but it can also metastasize to the central nervous system (CNS), which is quite uncommon.
- A case study describes a 65-year-old woman with EPSC who presented with neurological symptoms, leading to the discovery of a brain lesion indicative of cancer spread.
- The study suggests that EPSC can spread to unusual places like the CNS without systemic signs of disease, possibly through a specific venous drainage system in the body.
Article Abstract
Background: Endometrial papillary serous carcinoma (EPSC) is a rare gynecological malignancy that often metastasizes before the presentation of symptoms or diagnosis of the primary disease. The most common locations of metastases for this malignancy are the lungs, liver, and bones. Metastases to the central nervous system (CNS) are rare. Solitary CNS metastases without other anatomical site spread are exceedingly rare.
Observations: A 65-year-old female with a past medical history of EPSC presented with right-sided weakness, gait instability, and progressive dysarthria. Neurological evaluation revealed right hemiparesis and dysarthria. Head computed tomography showed an ovoid area of hypoattenuation in the left pons. Magnetic resonance imaging confirmed a 2.6-cm pontine lesion. A biopsy revealed histomorphology and immunophenotype consistent with metastasis of previously diagnosed serous carcinoma of the endometrium.
Lessons: Gynecological malignancies, in particular EPSC, can metastasize to atypical locations even without evidence of systemic disease. The authors hypothesize that this may be due to hematogenous spread through the Batson venous plexus. https://thejns.org/doi/10.3171/CASE24513.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633018 | PMC |
| http://dx.doi.org/10.3171/CASE24513 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multi‑omics identification of a novel signature for serous ovarian carcinoma in the context of 3P medicine and based on twelve programmed cell death patterns: a multi-cohort machine learning study.
Mol Med
January 2025
Department of Gynecology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Background: Predictive, preventive, and personalized medicine (PPPM/3PM) is a strategy aimed at improving the prognosis of cancer, and programmed cell death (PCD) is increasingly recognized as a potential target in cancer therapy and prognosis. However, a PCD-based predictive model for serous ovarian carcinoma (SOC) is lacking. In the present study, we aimed to establish a cell death index (CDI)-based model using PCD-related genes.
View Article and Find Full Text PDFMolecular Subgroups of HRD Positive Ovarian Cancer and Their Prognostic Significance.
Int J Mol Sci
December 2024
Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie st., 1, 115522 Moscow, Russia.
Homologous recombination repair deficiency (HRD) is involved in the development of high-grade serous ovarian carcinoma (HGSOC) and its elevated sensitivity to platinum-based chemotherapy. To investigate the heterogeneity of the HRD-positive HGSOC we evaluated the HRD status, including BRCA mutations, genomic scar score, and methylation status of genes in 352 HGSOC specimens. We then divided the HRD-positive cohort into three molecular subgroups, the BRCA mutation cohort (BRCA+), BRCA1 methylation cohort (Meth+), and the rest of the HRD+ cohort (HRD+BRCA-Meth-), and evaluated their first-line chemotherapy response, benefit from olaparib, and progression-free survival (PFS).
View Article and Find Full Text PDFEstablishment of Novel High-Grade Serous Ovarian Carcinoma Cell Line OVAR79.
Int J Mol Sci
December 2024
Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.
High-grade serous ovarian carcinoma (HGSOC) remains the most common and deadly form of ovarian cancer. However, available cell lines usually fail to appropriately represent its complex molecular and histological features. To overcome this drawback, we established OVAR79, a new cell line derived from the ascitic fluid of a patient with a diagnosis of HGSOC, which adds a unique set of properties to the study of ovarian cancer.
View Article and Find Full Text PDFHER2-Positive Serous Endometrial Cancer Treatment: Current Clinical Practice and Future Directions.
Medicina (Kaunas)
December 2024
5th Department of Oncology, Metropolitan General Hospital, 155 62 Athens, Greece.
The most common histological subtypes of endometrial cancer consist of endometrioid and uterine serous carcinoma, with the latter being more aggressive and accompanied by poor prognosis. Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor associated with cell proliferation, differentiation, and survival. HER2 positivity can be diagnosed in many solid tumors.
View Article and Find Full Text PDFElevated Galectin-3 levels in the tumor microenvironment of ovarian cancer - implication of ROS mediated suppression of NK cell antitumor response via tumor-associated neutrophils.
Front Immunol
January 2025
Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden.
Introduction: Ovarian cancer is a lethal disease with low survival rates for women diagnosed in advanced stages. Current cancer immunotherapies are not efficient in ovarian cancer, and there is therefore a significant need for novel treatment options. The β-galactoside-binding lectin, Galectin-3, is involved in different immune processes and has been associated with poor outcome in various cancer diagnoses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!